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Fig 1. A 52-year-old man with bullous pemphigoid
demonstrating numerous large, tense bullae and urticarial
plaques on the chest.
Fig 2. Bladder tissue from 52-year-old man with bullous
pemphigoid and cystitis showing many eosinophils
(broad arrow) and a subepithelial split (asterisk).
(Hematoxylin-eosin stain; original magnification: 3100.)
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newly diagnosed autoimmune bullous dermatoses,
including 4 individuals with BP, underwent
cystoscopy; of these patients, 13 had lower urinary
tract lesions. On pathology 2 patterns predominated:
nonkeratinizing squamous metaplasia and mucosal
inflammation of the bladder base. Among patients
with BP, the pathologic pattern of mucosal inflam-
mation prevailed (P ¼ .003).3
Limitations of this case include that the
subepithelial split on bladder biopsy specimen
could have been caused by trauma from the biopsy;
the biopsy specimen did however demonstrate
numerous eosinophils, which would be consistent
with BP. Direct immunofluorescence studies were
not performed on the bladder tissue. In addition, a
follow-up cystoscopy was not available to evaluate
whether the bladder lesions had cleared. An
interesting consideration is the atypical nature of
this patient’s BP. Given his age of onset (42 years),
concomitant psoriasis, and response to Enbrel (as
was initially used to treat his psoriasis, but also helped
resolve his BP), it is possible that this is a variant of
pemphigoid that is not yet described in the literature.Open access under CC BY-NC-ND license.Despite these limitations, given the cystoscopy
findings of bullae by the urologist, pathology
of the bladder epithelium on biopsy, and
that resolution of the patient’s urinary symptoms
coincided with resolution of his cutaneous
bullae, and typical immunofluorescence pattern
on salt-split skin for BP, this case seems to be most
consistent with symptomatic bladder involvement
of BP.
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Successful topical adapalene treatment for the
facial lesions of an adolescent case of
epidermolytic ichthyosis
To the Editor: Epidermolytic ichthyosis (EI) is a
keratinopathic ichthyosis that is characterized by
generalized multiple blisters and erosions with
erythroderma at birth. EI is caused by autosomal
dominant rarely recessive mutations in the keratin
1 gene (KRT1) or the keratin 10 gene (KRT10).
Their mutations lead to cytoskeletal fragility in
the upper epidermis. Here we report the successful
use of topical adapalene for treating a patient
with EI.
A 16-year-old Japanese male adolescent was
given the diagnosis of EI at birth. He was born with
erythrodermic skin, blisters, and erosions on the
whole body. As previously reported,1 mutation
analysis using the patient’s genomic DNA samples
revealed the heterozygous missense mutation
c.457C[G (p.Leu153Val) in KRT10. During the first
Fig 1. Epidermolytic ichthyosis. Clinical features of our patient. A, Before topical adapalene
treatment, thick dark-gray and brown scales are seen on the forehead.B, After topical adapalene
treatment, the hyperkeratosis is improved and thick scales are not seen on the forehead.
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and the erosions and blisters were replaced with
diffuse hyperkeratosis on almost the entire body
surface. The palms and soles were spared, as is often
the case with patients whose EI is caused by KRT10
mutations. He experienced diffuse pruritus on the
whole body. During his course, various treatments
implemented with modest efficacy included topical
vitamin D3, urea, steroids, and sulfadiazine.
When he was 14 years old, he began applying
topical adapalene gel 0.1% to his face. After 6 months
of treatment, his facial skin, mainly on the forehead,
became smoother and his facial appearance greatly
improved. He was satisfied with the results, and he
has continued to use topical adapalene. The skin
changes have persisted (Fig 1).
For hyperkeratotic lesions in EI, topical emollients
containing glycerin, lactic acid, urea, and white
petrolatum, along with topical vitamin D3
analogues are often used. Systemic retinoids are a
beneficial treatment, despite their several adverse
effects, for example, cheilitis, conjunctivitis, and
liver dysfunction. For pediatric cases, we sometimes
hesitate to use systemic retinoids because long-term
administration carries the risk of bone hypoplasia. In
light of this, topical application of retinoids is a
beneficial treatment for EI, especially for pediatric
patients, because a topical retinoid leads to less sys-
temic exposure to the agent than a systemic treatment.
A tretinoin derivative, adapalene is a third-
generation retinoid. To our knowledge, there are
no case reports in which ichthyosis was treated with
topical adapalene, although tazarotene, another
third-generation retinoid, was reported to be
effective for several types of ichthyosis, including
X-linked ichthyosis, lamellar ichthyosis, andichthyosis vulgaris.2,3 In the current case, we used
topical adapalene because topical adapalene causes
less irritation than topical tazarotene, and adapalene
is the only topical retinoid available in Japan.
Adapalene works to suppress the proliferation of
keratinocytes. Unlike tretinoin, adapalene does
not bind to the cytosolic retinoic acid binding
proteins, but selectively binds to the nuclear
retinoic acid receptors  and . The retinoic acid
receptor  subtype is predominantly expressed in
the epidermis.4 Several studies have suggested
that, because of this selectivity, adapalene may
demonstrate greater suppressive effect against
hyperkeratosis with milder side effects than other
retinoids demonstrate.5
For pediatric patients with EI, instead of systemic
retinoids, topical adapalene might be a useful and
powerful tool for improving facial lesions and quality
of life.
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